The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults: A Meta-analysis
Abstract
CONTEXT: Botulinum toxin A is US Food and Drug Administration approved for prophylactic treatment for chronic migraines. OBJECTIVE: To assess botulinum toxin A for the prophylactic treatment of headaches in adults. DATA SOURCES: A search of MEDLINE, EMBASE, bibliographies of published systematic reviews, and the Cochrane trial registries between 1966 and March 15, 2012. Inclusion and exclusion criteria of each study were reviewed. Headaches were categorized as episodic (<15 headaches per month) or chronic (≥15 headaches per month) migraine and episodic or chronic daily or tension headaches. STUDY SELECTION: Randomized controlled trials comparing botulinum toxin A with placebo or other interventions for headaches among adults. DATA EXTRACTION: Data were abstracted and quality assessed independently by 2 reviewers. Outcomes were pooled using a random-effects model. DATA SYNTHESIS: Pooled analyses suggested that botulinum toxin A was associated with fewer headaches per month among patients with chronic daily headaches (1115 patients, -2.06 headaches per month; 95% CI, -3.56 to -0.56; 3 studies) and among patients with chronic migraine headaches (n = 1508, -2.30 headaches per month; 95% CI, -3.66 to -0.94; 5 studies). There was no significant association between use of botulinum toxin A and reduction in the number of episodic migraine (n = 1838, 0.05 headaches per month; 95% CI, -0.26 to 0.36; 9 studies) or chronic tension-type headaches (n = 675, -1.43 headaches per month; 95% CI, -3.13 to 0.27; 7 studies). In single trials, botulinum toxin A was not associated with fewer migraine headaches per month vs valproate (standardized mean difference [SMD], -0.20; 95% CI, -0.91 to 0.31), topiramate (SMD, 0.20; 95% CI, -0.36 to 0.76), or amitriptyline (SMD, 0.29; 95% CI, -0.17 to 0.76). Botulinum toxin A was associated with fewer chronic tension-type headaches per month vs methylprednisolone injections (SMD, -2.5; 95% CI, -3.5 to -1.5). Compared with placebo, botulinum toxin A was associated with a greater frequency of blepharoptosis, skin tightness, paresthesias, neck stiffness, muscle weakness, and neck pain. CONCLUSION: Botulinum toxin A compared with placebo was associated with a small to modest benefit for chronic daily headaches and chronic migraines but was not associated with fewer episodic migraine or chronic tension-type headaches per month.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884
A Re-Evaluation of Random-Effects Meta-Analysis
Higgins, J. P. T., Thompson, S. G., & Spiegelhalter, D. J. (2009) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2008.00552.x · Cited by 2,569
Effect Sizes for Interpreting Changes in Health Status
Kazis, L. E., Anderson, J. J., & Meenan, R. F. (1989) · Medical Care · doi:10.1097/00005650-198903001-00015 · Cited by 2,401
Blumenfeld, A., Varon, S., Wilcox, T., Buse, D., Kawata, A., Manack, A., Goadsby, P., & Lipton, R. (2011) · Cephalalgia · doi:10.1177/0333102410381145 · Cited by 627
The Family Impact of Migraine: Population-Based Studies in the USA and UK
Lipton, R., Bigal, M., Kolodner, K., Stewart, W., Liberman, J., & Steiner, T. (2003) · Cephalalgia · doi:10.1046/j.1468-2982.2003.00543.x · Cited by 214
Cited by
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology
Pirazzini, M., Rossetto, O., Eleopra, R., & Montecucco, C. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012658 · Cited by 768
Chronic migraine: risk factors, mechanisms and treatment
May, A., & Schulte, L. H. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.93 · Cited by 630
Management of functional somatic syndromes and bodily distress
Henningsen, P., Zipfel, S., Sattel, H., & Creed, F. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000484413 · Cited by 335
A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache
Jackson, J. L., Cogbill, E., Santana-Davila, R., Eldredge, C., Collier, W., Gradall, A., Sehgal, N., & Kuester, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130733 · Cited by 291
Powers, S. W., Kashikar-Zuck, S. M., Allen, J. R., LeCates, S. L., Slater, S. K., Zafar, M., Kabbouche, M. A., O’Brien, H. L., Shenk, C. E., Rausch, J. R., et al. (2013) · JAMA · doi:10.1001/jama.2013.282533 · Cited by 287
Metadata
- Authors
- Kuriyama, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2012-04-25
- Volume
- 307
- Issue
- 16
- Pages
- 1736
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2127941826
- Cited by
- 218
- References
- 6
- FWCI
- 16.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults: A Meta-analysis. https://app.cochat.ai/papers/10.1001/jama.2012.505
- The paper
- Kuriyama, A. (2012). Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults: A Meta-analysis. JAMA. https://doi.org/10.1001/jama.2012.505
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.